Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has published below its audited results for the year ended 30 September 2024.
Non-Executive Directors’ Statement
Introduction
The key priority for the Directors is to focus on the Company’s NXP002 lead programme to find a business development partner to secure the financial future of the Group. The Group operates a lean structure with the limited Board and brings in specialist consultants, experts in their field, to support the business as required.
Pipeline
Nuformix has a small pipeline of preclinical assets in development to address the high unmet medical need in fibrosis and oncology. We target solutions using our expertise to develop and file patent applications on novel crystalline forms of existing, marketed drugs, that have improved physical properties, with the aim of developing novel products in new indications to create attractive commercial opportunities. Importantly, the commercial opportunity is optimised when the repurposed product is differentiated from the original marketed product by way of either dose, route of administration or presentation.
